ARTICLE | Product Development
Gilead reveals promising data from compassionate use of remdesivir, first clinical data due in May
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 11, 2020 12:51 AM UTC
Updated on Apr 11, 2020 at 1:38 AM UTC
The first glimpse of data for Gilead’s remdesivir show the antiviral improved the symptoms in 68% of patients hospitalized with severe COVID-19; however, the company will have to wait until next month for data from more robust clinical trials of the closely-watched program.
Gilead Sciences Inc. (NASDAQ:GILD) said Friday that 36 of 53 patients with severe COVID-19 complications had an improvement in oxygen support class over a median follow-up of 18 days from the first dose. Of the 30 patients on ventilators, 17 (57%) were extubated. Patients received the therapy on an individual compassionate use basis...
BCIQ Company Profiles